miophthalmology products
VF2000 Neo
The VF2000 Neo compact portable virtual reality visual field device offers an extensive range of visual field (VF) tests including Fast Threshold VF, frequency doubling technology (FDT) perimetry, neuro, kinetic, ptosis, and Esterman tests. Active eye tracking pauses and alerts the patient during testing if they lose fixation or close their eyes.
Supplied complete with a tablet device, test results are stored and accessed from the tablet and automatically uploaded to the cloud for retrieval on any personal computer through the user’s portal. Furthermore, software enables test results to be automatically downloaded to any Windows device.
With no need for a dedicated space, a darkened room, or an eye patch for occlusion, the VF2000 Neo can be used anywhere to provide a comfortable relaxing experience.
Virtual assistance guides the patient and enables communication in multiple languages.
Manufactured by Micro Medical Devices in the United States.
Contact: BOC Instruments (AUS) 1800 804 331 or sales@bocinstruments.com.au
Tango Neo
Published in The Lancet, the pivotal results of the LiGHT trial conclude that selective laser trabeculoplasty (SLT) should be used as the preferred first-line treatment for patients with glaucoma or ocular hypertension.1
Around the world, thousands of physicians are deploying this procedure as a primary therapy tool that stimulates the eye’s natural healing response to effectively manage their patients’ intraocular pressure without the burn and scar tissue associated with argon laser trabeculoplasty (ALT).
With Tango Neo you can use SLT to determine the location of the pathology and treat glaucoma effectively and safely for better patient outcomes.
Contact: salesadmin@ellex.com
Reference
1. Gazzard G et al. LiGHT study, The Lancet. doi: 10.1016/S0140-6736(19)31503-X.
Glaukos iStent
iStent technology has revolutionised the treatment of glaucoma in Australia since its introduction in 2016. As the tiniest implantable device in the human body, and with over one million successful implantations worldwide, it has been a game changer for patients diagnosed with glaucoma by effectively reducing eye pressure and medication burden.
The latest addition to the iStent family – iStent infinite – is now available.
iStent infinite is designed to provide foundational, 24/7 therapy that gives you the power to deliver optimised treatment for patients with primary open angle glaucoma, currently treated with glaucoma medication – including those who have failed prior medical or surgical intervention – while minimising the unwanted side effects of more invasive treatment options.
iStent infinite is approved by the Therapeutics Goods Administration and on the prescribed list of medical devices.
Contact: Glaukos Account Manager
iCare ST500
The iCare ST500 is the world’s first rebound tonometer designed specifically for slit lamp use, offering efficient, rapid, and accurate measurement of intraocular pressure (IOP). This innovative device is compatible with most slit lamps that feature an 8 mm focus rod mounting hole, ensuring ease of integration into existing clinical setups.
The probe installation is straightforward with the applicator, which simplifies the setup process. The SmartCradle further enhances the user experience by providing a dedicated space for the tonometer adapter, probe applicator, probe box, and an optional remote control, ensuring all essential components are organised and readily accessible.
Visit: icare-world.com/product/st500
Medmont Meridia Pro
When treating glaucoma, it pays to have a topographer with dry eye assessment capabilities – like the Medmont Meridia Pro – in your instrument lineup. That’s because glaucoma treatments can increase the risk of dry eye and vice versa.1 The Medmont Meridia Pro offers tear film analysis and fluorescein imaging, as well as a high-definition colour camera that effortlessly captures detailed photographs and video for robust pathology documentation. Anterior imaging with white light allows you to confidently evaluate redness and inflammation, blepharitis, eyelid hygiene, meibomian gland expression, and more.
Contact: jason@medmont.com
Reference
1. Berdahl J, Managing corneal disease and glaucoma, Review of Ophthalmology, 2020, available at: reviewofophthalmology.com/article/managing-corneal-disease-and-glaucoma [accessed Jan 2024].
Olleyes VR Software
The Olleyes VisuAll is transforming the world of vision testing and perimetry with its cutting-edge features. Designed for productivity, this fully automated platform enables providers to control multiple devices simultaneously, streamlining workflow. Its portability stands out – lightweight and compact, it can be transported to any location, whether in-office or at-home testing.
Patients benefit from the VisuAll’s comfort and ergonomic design, which allows tests to be conducted in any position with a hygienic, easily disinfected face cushion that ensures comfort throughout. Additionally, its advanced ambient control enables testing in any lighting conditions – even in a brightly lit waiting room. The VisuAll is a game changer for vision testing, seamlessly combining innovation, convenience, and patient comfort.
Contact: Ophthalmalogic (AUS) 0431 002 302
Topcon NW500 (RIGHT)
Topcon’s next-generation fundus imaging camera, the NW500, offers bright and sharp images in well-lit conditions, even for eyes with small pupils.* Capable of capturing fundus images through a pupil diameter as small as 2.0 mm,* it provides sharp, detailed colour fundus images in dark and brightly lit rooms. The slit-scan mechanism helps to overcome one of the known causes of poorly graded images with its ability to effectively image through small pupils. This innovative technology also helps the NW500 capture sharp, high-quality fundus images, regardless of miosis and the lighting conditions, unlike conventional fundus cameras.
Visit: topconhealthcare.com.au
* φ2.0 mm or larger, tested on model eye.
LKC Reteval
The LKC Reteval is a portable device that enhances glaucoma management through electroretinography (ERG). Using skin electrodes, it avoids corneal contact and pupil dilation, making it comfortable and easy to use. The Reteval measures the photopic negative response, specific to ganglion cells, providing crucial information about their function. This helps in diagnosing and monitoring glaucoma by detecting functional changes before structural damage occurs.
The LKC Reteval’s advanced algorithm ensures consistent and reliable results, while colour-coded outcomes simplify interpretation. This non-invasive tool is efficient for monitoring disease progression and treatment efficacy, even in patients with media opacities like cataracts. The Reteval represents a significant advancement in early detection and ongoing management of glaucoma.
Contact: quentin@ophthalmix.com.au
Huvitz OCT
A combination of a full-colour fundus camera, personal computer, and optical coherence tomography (OCT) in one, Huvitz OCT provides high-speed scanning and delivers high-resolution images, making extensive examination and instant diagnostic results possible.
Its anterior segment module allows measurement and analysis of cornea thickness, angle, and 3D imaging. It helps users work more efficiently by acquiring both anterior and posterior images in one place. The measurement of anterior chamber angle (ACA) between the cornea and iris allows diagnosis and management of angle-closure glaucoma patients.
Along with other features, Huvitz is a powerhouse OCT that can be used for early diagnosis of glaucoma and many other diabetic eye diseases, including diabetic retinopathy, diabetic macular oedema, and cataracts.
Contact: Opticare (AUS) 1800 251 852
Optomap
Optomap delivers detailed imaging from pole to periphery, allowing glaucoma specialists to effortlessly examine the entire posterior segment – even through a 2 mm pupil or a +3 dense cataract.
By incorporating optomap into examinations, specialists can confidently assess the entire retina, with studies showing a 30% increase in pathology detection compared to direct observation alone.1
With 97% of optomap users reporting the identification of unexpected pathologies in patients without visual complaints,2 this advanced technology empowers glaucoma specialists to provide superior glaucoma care and efficiently detect retinal diseases with precision.
Visit: optos.com
References available at mivision.com.au.
ZEISS Glaucoma Workplace
Preserving glaucoma patient’s vision requires the ability to make the right decisions at the right time. Making those decisions with confidence starts with detecting change as early as possible.
ZEISS Glaucoma Workplace integrates data from the Humphrey field analyser (HFA) and Cirrus optical coherence tomography (OCT), providing guided progression analysis across multiple generations of devices, to maintain an uninterrupted view of a patient’s structural and functional progression. This complete assessment is visible in one single display accompanied by fundus images and intraocular pressure documentation.
The accompanying Glaucoma Workplace example demonstrates a pre-perimetric case, whereby structural change was detected by Cirrus OCT four years prior to functional loss detection in the HFA visual fields. An important clinical example of how both modalities are essential in providing a full assessment.
Contact: ZEISS Surgical Account Manager
Ganfort and Lumigan Patient Adherence Programme
Patients prescribed Ganfort, or Ganfort PF (bimatoprost/timolol) and Lumigan, or Lumigan PF (bimatoprost) eye drops can be enrolled in AbbVie’s free two-year programme, which provides them with ongoing support through their glaucoma journey.
In addition to timely reminders to use their medication, enrolled patients receive a series of messages on their device via SMS or the MedAdvisor app, arriving at pre-determined intervals: 12 messages in year one and nine messages in year two.
As of August 2024, over 8,000 patients were enrolled on the AbbVie adherence programmes. Patients enrolled in the programme have been dispensed 7.31 additional scripts versus patients not enrolled on the programme. AbbVie has reported a 69% incremental uplift on persistence to treatment for new patients after 24 months on the adherence programme.
Visit: abbvie.com.au/our-science/products.html
Hydrus Microstent
The Hydrus Microstent is an innovative canal-based, minimally invasive glaucoma surgery (MIGS) device for patients with mild-to-moderate primary open-angle glaucoma. This device is the only MIGS implant to span approximately 90° of Schlemm’s canal, ensuring access to collector channels in the nasal region.1-3 The first MIGS device to precisely dilate and scaffold Schlemm’s canal, it gently expands the cross sectional area without obstructing outflow access to collector channel ostia.1-3 The Hydrus Microstent bypasses the trabecular meshwork to restore flow of aqueous from the anterior chamber through the inlet of the microstent into Schlemm’s canal.1
The Hydrus Microstent comes preloaded in a single-use hand-held delivery system featuring:
1) A tracking wheel for controlled delivery, 2) A rotatable cannula ensuring positioning and alignment for arange of hand positions, and 3) A cannula tip designed to match curvature of the trabecular meshwork.
Hydrus is the first and only MIGS device to report clinical outcomes from a pivotal trial with five years of continuous follow-up – achieving 80% retention at year five.4 The long-term results show that 59% of Hydrus patients remained medication-free at five years.5
Contact: Alcon Account Manager
Please refer to product direction for use for list of indications, contraindications and warnings.
References
1. Hydrus Microstent instructions for use. 2. Samuelson TW, et al. doi: 10.1016/j.ophtha.2018.05.012. 3. Market Scope 2021, Glaucoma surgical device market report:
2020-2026. July 2021. 4. Ahmed IIK, De Francesco T, Singh K, et al. doi:10.1016/j.ophtha.2022.02.021 5. Alcon data on file, 2024.
Optopol PTS 2000
The Optopol PTS 2000 is a top-of-the-line projection perimeter with modern and intuitive software available at your fingertips. From quick screening tests to manually controlled kinetic perimetry, the PTS 2000 offers one of the world’s largest field-testing ranges. It includes all Goldmann stimuli sizes and colours used in perimetry, ensuring comprehensive and accurate results.
The Zeta Threshold algorithms allow for patient testing in under three minutes. Key features, such as eye tracking, head tracking, blink detection, and voice guidance ensure a seamless testing experience. Additionally, Defect Progression Analysis simplifies disease monitoring by establishing a baseline and tracking progression over time.
The Optopol PTS 2000 combines precision, efficiency, and advanced technology to elevate your practice and enhance patient care.
Contact: Optimed (AUS) 1300 657 720
Melbourne Rapid Fields
Melbourne Rapid Fields (MRF) online perimetry revolutionises visual field testing with its artificial intelligence-driven, web-based platform, enabling seamless testing on any digital computer. A groundbreaking study recently published in Frontiers in Ophthalmology1 validated MRF’s clinical excellence in a multicentre trial with 232 patients. The results showcased MRF’s ability to deliver accurate, white-on-white perimetry outcomes equivalent to HFA SITA-Faster, regardless of location – be it metropolitan or rural – or the digital device used. With exceptional sensitivity and specificity across the full spectrum of glaucoma, MRF sets a new standard in portable perimetry testing. This innovative solution empowers healthcare professionals with unmatched flexibility, clinical precision, and efficiency, making it an indispensable tool for managing glaucoma both in clinics and remote settings.
Contact: Glance Optical (AUS) 1800 225 307 or info@glance-optical.com
Reference
1. Tiang J, et al. Frontiers in Ophthalmology. doi: 10.3389/fopht.2025.1485950.
iTrack Advance: Elevating Canaloplasty (LEFT)
The iTrack Advance is a state-of-the-art canaloplasty microcatheter that offers an implant-free minimally invasive glaucoma surgery (MIGS) solution for mild to moderate glaucoma. Equipped with an illuminated tip for enhanced visibility, the iTrack Advance can target and treat blockages within Schlemm’s canal, the collector channels, and the trabecular meshwork, via a process of 360° catheterisation and viscodilation.
Clinicians trust iTrack Advance for its ability to optimise outflow and reduce intraocular pressure while preserving the eye’s natural anatomy. The device’s minimally invasive approach leads to faster recovery times and improved patient outcomes.
Contact: info@nova-eye.com
SightScore Glaucoma Genetic Risk Assessment
SightScore is a saliva-based test that analyses thousands of genetic variants in a patient’s DNA to create a personalised polygenic risk score for primary open angle glaucoma. SightScore enables optometrists and ophthalmologists to triage patients according to their risk of glaucoma and glaucoma progression:
• Family members: Identify which patients have inherited high genetic risk to inform eye examination and monitoring-frequency decisions. • Glaucoma suspects/ocular hypertension: Identify patients at risk of conversion to glaucoma for monitoring and referral decisions. • Glaucoma cases: Identify patients at risk of more severe glaucoma and surgery.
SightScore is based on world-leading research and has been validated in large clinically relevant cohorts.1
Visit: seonixbio.com
Reference
1. Craig J, Han X, Qassim A., et al. doi: 10.1038/s41588-019-0556-y.
Miniject for MIGS
Miniject is iSTAR Medical’s innovative microinvasive glaucoma surgery (MIGS) device for patients with open-angle glaucoma.
Miniject combines the distinctive porous structure of its proprietary Star material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis, and subsequent complications.
Three-year follow-up results demonstrate sustained, meaningful, mean IOP reduction of 36%, with 42% of patients medication-free. Mean endothelial cell density loss at three years was 9% (less than for cataract surgery at two years).1
Contact: istar-medical.com
Reference
1. Provisional interim results up to three years. Data on file.
Dedicated Glaucoma Management Services
Patients seeking glaucoma management can be referred to the Australian College of Optometry (ACO) Eye Health’s dedicated clinic in Carlton, in inner-city Melbourne. Led by optometrists with comprehensive training in glaucoma, this clinic supports patients who may struggle to access ophthalmology care.
The advanced glaucoma service provides vital care for glaucoma and glaucoma suspect patients, particularly those whose condition falls outside the Victorian Statewide Referral Guidelines and do not qualify to attend a public hospital ophthalmology service.
In addition to services at Carlton, all ACO Eye Health Melbourne clinics are equipped with Humphry field analysers, optical coherence tomography, and fundus photography, allowing ACO to detect and monitor glaucoma, as well as other eye conditions. Patients requiring further input from ophthalmology will be suitably referred for tertiary care.
Contact: ACO (AUS) 03 9349 7455 or email: appointments@acoeyehealth.org.au
iCare IC200
iCare IC200 is the most versatile tonometer in iCare’s tonometry portfolio. This flagship device offers a Quick Measure feature to capture intraocular pressure (IOP) measurements faster and easier than before. By capturing IOP with just two or three individual measurements instead of the standard six, test times are shorter. Additionally, with 200º of positional freedom, the iCare IC200 can measure IOP whether the patient is supine, reclined, or seated, which is especially useful in clinical, surgical, or emergency settings.
Contact: Designs for Vision (AUS) 02 9509 8100
Disclaimer: The opinions expressed in this section do not necessarily reflect the opinion of Toma Publishing or its subsidiaries.